FasciolaDNA疫苗的免疫原性和功效尚未以系统评价和荟萃分析的形式进行全面总结。尽管存在关于Fasciola疫苗的多种疫苗研究,实验参数的差异使比较变得困难。我们在Scopus进行了书目数据库搜索,PubMed,科学直接,科克伦图书馆,EMBASE和WebofScience数据库,限于1998年至2017年的出版物。关键词:肝吸虫,肝片吸虫,巨大的Fasciola,DNA疫苗接种,和免疫原性组合使用以形成搜索字符串。初步筛选后,总共确定了4760项研究,其中14人符合系统评价标准,7人符合荟萃分析标准。所有研究的平均赔率比(OR)为0.565(95%置信区间(CI)为0.293至1.087),这意味着在接种DNA疫苗的动物中,减少吸虫负担的保护百分比为43.5%。观察到半胱氨酸蛋白酶和磷酸甘油酸激酶疫苗抗原候选物的中等保护效力(合并OR和95%CI,[0.542;0.179-1.721]和[0.616;0.219-1.735],分别)。在个别研究和队列中观察到疫苗的有效性;然而,所有候选疫苗的总体汇总疗效均不显著.尽管多项个别研究显示各种DNA疫苗候选物抗筋膜病的有希望的结果,汇总研究表明,疫苗制剂对吸虫负担的影响不显著,并显示出对Fasciola感染的最小保护功效。虽然在孤立的研究中观察到有希望的结果,需要进一步进行具有标准化实验参数的动物试验,以开发有效对抗Fasciola的新候选疫苗.
The immunogenicity and efficacy of Fasciola DNA vaccines have not yet been comprehensively summarised in the form of a systematic
review and meta-analysis. Though multiple vaccine studies with respect to Fasciola vaccines exist, the variance in the experimental parameters has made comparison difficult. We conducted a bibliographic database search in Scopus, PubMed, Science Direct, Cochrane Library, EMBASE and Web of Science databases, limited to publications from 1998 to 2017. The key words: Liver fluke, Fasciola hepatica, Fasciola gigantica, DNA vaccination, and immunogenicity were used in combination to form search strings. A total of 4760 studies were identified after initial screening, of which 14 qualified for systematic
review and 7 for meta-analysis. The mean Odds Ratio (OR) for all studies was 0.565 (95% confidence interval (CI) of 0.293 to 1.087), which means the percentage of protection in terms of decreased fluke burden in animals vaccinated with DNA vaccines was 43.5%. A moderate protective efficacy was observed for cysteine protease and phosphoglycerate kinase vaccine antigen candidates (pooled OR and 95% CI, [0.542; 0.179-1.721] and [0.616; 0.219-1.735], respectively). Vaccine effectiveness was observed in individual studies and cohorts; however, the overall pooled efficacy for all vaccine candidates was found to be non-significant. Despite multiple individual studies showing promising results for various DNA vaccine candidates against fascioliasis, the pooled studies showed the non-significant effect of the vaccine formulations against fluke burden, and displayed minimal protective efficacy against Fasciola infection. Though promising results are observed in isolated studies, further animal trials with standardised experimental parameters are required to develop new vaccine candidates effective against Fasciola.